Stock J90 NUREXONE BIOLOGIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NurExone Biologic Inc. Deutsche Boerse AG

Equities

J90

CA67059R1091

Real-time Estimate Tradegate
Other stock markets
 02:49:03 2024-07-18 am EDT 		5-day change 1st Jan Change
0.478 EUR -1.24% Intraday chart for NurExone Biologic Inc. +15.38% +180.70%
Jul. 17 NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone?s First Product ExoPTEN for Glaucoma CI
Jun. 28 NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
AQ
NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone?s First Product ExoPTEN for Glaucoma
CI
Updates from NurExone: Growth Conference Presentation and Website Relaunch
AQ
NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves
CI
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
AQ
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
AQ
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
AQ
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
AQ
NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
AQ
NurExone Biologic Announces OTCQB Listing And DTC Eligibility
MT
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
AQ
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRX Stock
  4. J90 Stock
  5. News NurExone Biologic Inc.